Ellington Management Group’s Ligand Pharmaceuticals LGND Stock Holding History

Ellington Management Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,809	Closed	-$823K	–	506
2018 Q3	$823K	Sell	4,809 -1,443	-23%	-$218K	0.22%	124
2018 Q2	$808K	Sell	6,252 -2,885	-32%	-$322K	0.06%	97
2018 Q1	$941K	Buy	+9,137	New	+$904K	0.07%	215
2016 Q4	–	Sell	-3,206	Closed	-$204K	–	688
2016 Q3	$204K	Buy	+3,206	New	+$235K	0.06%	535
2016 Q2	–	Sell	-3,046	Closed	-$203K	–	384
2016 Q1	$203K	Buy	+3,046	New	+$185K	0.09%	392
2015 Q3	–	Sell	-4,649	Closed	-$293K	–	806
2015 Q2	$293K	Buy	+4,649	New	+$254K	0.07%	437
2015 Q1	–	Sell	-7,855	Closed	-$261K	–	757
2014 Q4	$261K	Buy	+7,855	New	+$256K	0.09%	370
2013 Q4	–	Sell	-34,144	Closed	-$922K	–	683
2013 Q3	$922K	Buy	+34,144	New	+$961K	0.17%	132

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Ellington Management Group's LGND Position: Q4 2018 in Review

Ellington Management Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 4,809 shares — an estimated $823K sold.

Ellington Management Group first reported a position in LGND in Q3 2013 and held it in 8 quarters. The position peaked at $941K in Q1 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Ellington Management Group reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ellington Management Group sold 4,809 Ligand Pharmaceuticals shares in Q4 2018, an estimated $823K.
Ellington Management Group first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Ellington Management Group's Ligand Pharmaceuticals position peaked at $941K in Q1 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Ellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.